<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1911246280
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GLITRA 2MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GLIMEPIRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BB12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>GLITRA is the trademark of Glimepiride, an Antidiabetic agent.<br />&nbsp;</p><p><strong>INDICATIONS</strong><br />Non-insulin-dependent (type II) diabetes, whenever blood sugar levels cannot be controlled adequately by diet, physical exercise and weight reduction alone. Glimepiride may also be used in combination with an oral antidiabetic containing metformin or with insulin</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>CONTRAINDICATIONS</strong><br />Glimepiride is contraindicated in patients with<br />&nbsp;Known hypersensitivity to Glimepiride, other Sulfonylureas, or other sulfonamides.&nbsp;<br />Insulin-Dependent Diabetes mellitus (type 1), diabetic ketoacidosis, with or without coma. This condition should be treated with insulin.&nbsp;<br />In patients with severe impairment of renal or hepatic function, a changeover to insulin is indicated.&nbsp;<br />&nbsp;Pregnancy and lactation.<br /><strong>WARNINGS</strong><br />In the initial weeks of treatment, the risk of hypoglycemia may be increased and necessitates especially careful monitoring.<br />The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin.&nbsp;<br />Adrenal insufficiency, Debilitated physical condition, Hepatic function impairment, Malnutrition, Pituitary insufficiency or Renal function impairment: these conditions may cause increased sensitivity to the glucose-lowering effect of Glimepiride; therapy with Glimepiride should be initiated at the minimum recommended dose in these patients.<br />High fever, Infection, Surgery or Trauma: these conditions may cause loss of glycemic control; temporary therapy in combination with insulin or with insulin alone may be necessary.&nbsp;<br /><br /><strong>PRECAUTIONS&nbsp;</strong><br />-Blood and urine glucose determinations: periodic monitoring recommended to determine therapeutic efficacy.&nbsp;<br />-daily monitoring of capillary blood glucose recommended in stable diabetics using combination insulin-Glimepiride therapy.<br />-Glycosylated hemoglobin (hemoglobin A 1c) determinations: monitoring recommended every 3 to 6 months to assess long-term glycemic control.<br />-Patients should always carry at least 20 gm of glucose with them because hypoglycemia can almost always be promptly controlled by immediate intake of &nbsp;sugar.(food or beverages containing artificial sweeteners such as diet foods or drinks are ineffective in controlling hypoglycaemia)&nbsp;</p><p>-a switch over from other oral hypoglycaemic agents to Glimpepiride can generally be done . for the switch over to&nbsp;Glimpepiride the strength and half life of the previous medication has to be taken into account. in some cases, especially in antidiabetics with long half life (e.g chlorpropamide) , a wash out period of a few days is advisable in order to minimise the risk of hypoglycaemic reactions due to additive effect.</p><p><strong>USE IN PREGNANCY</strong><br />Studies have not been done in humans. Based on the results of animal studies, Glimepiride is not recommended for use during pregnancy. FDA Pregnancy Category C.&nbsp;<br /><strong>USE IN LACTATION</strong><br />It is not known whether Glimepiride is distributed into human breast milk. However, some sulfonylureas are distributed into human breast milk.<br />In reproduction studies, significant concentrations of Glimepiride were observed in the milk of rats and in the serum of their pups. Because of its potential to cause hypoglycemia in nursing infants, and because of its effect on nursing animals, Glimepiride is not recommended for use by nursing mother</p><p><strong>Drug interactions:</strong></p><p>- Sympatholytics, such as beta-adrenergic blocking agents:&nbsp; sympatholytics may blunt some of the symptomes of developing hypoglycemia, making detection of this condition more difficult.</p><p>- Alcohol or highly protein -bound medications such as: anti-inflammatory drugs , nonsteroidal ( NSAIDs), anticoagulants, coumarin-derivative, chloramphernicol, monoamine oxidase inhibitors, probencid , Salicylates and sulfonamides: these medications enhance the hypoglycemic effects of sulfonylyureas when given concurrently.</p><p>- Hyperglycemia causing agent such as : corticosteroids, diuretics, estrogens, isoniazid Niacin, Oral contraceptive, phenothiaziens, phenytoin, sympathomimetic agents and thyroid hormones: these medications may cause loss of glycemic control.</p><p>- severe hypoglycemia has been reported shortly after concurrent use of some sulfonylureas with miconazole.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DOSAGE</strong><br /><u>Usual adult dose&nbsp;</u><br />-Monotherapy<br />Initial: 1 mg once a day with breakfast or the first main meal. If necessary, the daily dose can be increased. Any increase should be based on regular blood sugar monitoring, and should be gradual, i.e., at intervals of one to two weeks, and carried out stepwise.&nbsp;<br />Maintenance: 1 to 4 mg once a day. After reaching a dose of 2 mg, increases in dosage should be made in increments of up to 2 mg every one to two weeks based on blood glucose response.&nbsp;<br />-Use in combination with metformin: Whenever blood sugar levels cannot be controlled adequately with the maximum daily dose of either GLITRA or a metformin-containing antidiabetic alone, both medicines may be used concomitantly. In such cases, the dose of the established medicine remains unchanged. Treatment with the additional medicine is started at a low dose, which depending on the desired blood sugar level may then be increased gradually up to the maximum daily dose. Combined treatment should be initiated under close medical supervision.&nbsp;<br />-Use in combination with insulin: Whenever blood sugar levels cannot be controlled adequately with the maximum daily dose of GLITRA, insulin may be given concomitantly. In this case, the current dose of GLITRA remains unchanged. Insulin treatment is started at a low dose, which is subsequently increased stepwise according to the desired blood sugar level. Combined treatment should be initiated under close medical supervision.&nbsp;<br /><strong>Notes</strong><br />-Safety and efficacy have not been established in children.&nbsp;<br />-GLITRA must be swallowed without chewing and with sufficient amounts of liquid (approximately 1/2 glass) and taken at the times and in the doses prescribe</p><p><strong>OVERDOSE&nbsp;</strong><br />Overdosage of sulfonylureas including Glimepiride can produce hypoglycemia.<br />Specific treatment need for overdose: Mild hypoglycemia symptoms without loss of consciousness or neurologic findings should be treated with immediate ingestion of glucose and adjustments to medication dosage and/or meal patterns. However, severe hypoglycemia including coma, seizures, requires immediate emergency medical assistance. The patient should immediately be given an intravenous injection of a 50% glucose solution followed by a continuous infusion of a 10% glucose solution to maintain a blood glucose concentration of 100 mg per dL. Patients with severe hypoglycemia should be monitored for at least 24 to 48 hours.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Incidence less frequent:</u> Hypoglycemia.<br /><u>Incidence rare: </u>Allergic skin reactions; blurred vision and/or changes in accommodation; hyponatremia, Diarrhea, dizziness, gastrointestinal pain, headache, nausea, unusual tiredness or weakness, vomiting, thrombopenia</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>store according to conitions specified on the package.</p><p>Do not use after the expiry date shown on the package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>GLITRA is the trademark of Glimepiride, an Antidiabetic agent.<br />Each GLITRA 1, 2, 3 and 4 tablet contains Glimepiride 1, 2,3 and 4 mg, respectively</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -How of 30 blistered tablets of Glitra 1
-How of 30 blistered tablets of Glitra 2
-How of 30 blistered tablets of Glitra 3
-How of 30 blistered tablets of Glitra 4

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Jordanian Pharmacetical Manufacturing Co.(P.L.C)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2005
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>جليترا هو الاسم التجاري لجليمبرايد، وهو عامل مضاد للسكري</p><p><strong>الاستطبابات</strong><br />السكري غير المعتمد على الأنسولين (نوع 2)، عندما لا يمكن السيطرة على مستويات سكر الدم بشكل كاف بواسطة الحمية والتمارين الرياضية وتخفيف الوزن لوحدهم. يمكن توليف جليمبرايد مع الأدوية المضادة للسكري الفموية المحتوية على ميتفورمين أو مع الأنسولين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>مضادات الاستطباب</strong><br />يضاد استطباب جليمبرايد في المرضى المصابين ب</p><p>فرط الحساسية المعروفة لجليمبرايد، سلفونيل يوريات أخرى، أو سلفوناميدات أخرى<br />السكري المعتمد على الانسولين (نوع 1)، حماض كيتوني سكري، مع أو بدون غيبوبة. يجب أن تعالج هذه الحالة بالأنسولين<br />في المرضى المصابين بقصور كلوي أو كبدي وظيفي حاد، يستبدل العلاج بأنسولين<br />الحمل والإرضاع<br /><strong>التحذيرات</strong><br />في الأسابيع الأولى من العلاج، يمكن أن يزيد من خطر نقص سكر الدم لذا يستلزم مناطرة حذره خاصة<br />ورد أن اعطاء الأدوية المنقصة لسكر الدم الفموية مرتبطة بزيادة معدل الوفيات الناتجة عن القلبية الوعائية بالمقارنة مع العلاج بالحمية لوحدها أو الغذاء مع الأنسولين<br />القصور الكظري او حالة الضعف البدني او قصور الكبد الوظيفي او سوء التغذية او قصور الغدة النخامية او قصور كلوي وظيفي: هذه الحالات يمكن أن تسبب زيادة الحساسية إلى تأثير جليمبرايد المخفض للغلوكوز، لذا يجب أن يبدأ العلاج بجليمبرايد بالحد الأدنى للجرعة الموصوفة لهؤلاء المرضى<br />الحمى الشديدة، العدوى، الجراحة أو الرضوح: هذه الحالات يمكن أن تسبب فقد السيطرة على &nbsp;سكر الدم، لذا قد يكون من الضروري أن يعالج مؤقتاً بالترافق مع الأنسولين أو بالأنسولين وحده<br />فرط الجرعة<br />يمكن لفرط الجرعة بسلفونيل يوريات ويتضمن جليمبرايد ان يسبب نقص سكر الدم<br />يحتاج فرط الجرعة إلى علاج خاص<br />يجب أن يعالج أعراض نقص سكر الدم الخفيف بدون فقدان للوعي أو نتائج عصبية بتناول فوري للغلوكوز وتعديل نمط جرعات الدواء و/أو الوجبات ولكن نقص سكر الدم الحاد الذي يتضمن غيبوبة ونوبات فيتطلب مساعدة طبية طارئة فورية. ويجب أن يحقن المريض وريدياً بـ50% محلول الغلوكوز ثم يتبعه بحقن مستمر لـ 10% محلول غلوكوز للحفاظ على تركيز غلوكوز الدم 100 ملغم/ دسليتر<br />يجب أن يراقب المصابين بنقص سكر الدم الحاد لمدة 24-48 ساعة على الأقل<br /><strong>الاحتياطات</strong><br />تحديد غلوكوز الدم والبول: تنصح بمراقبة دورية لتحديد الكفاءة العلاجية<br />ينصح بمراقبة يومية لغلوكوز الدم الشعري في السكري المستقر الذي يستعمل ترافق الأنسولين- جليمبرايد<br />تحديد الهيموغلوبين الغليكوزيلاتي (هيموغلوبين A 1c): ينصح بالمراقبة كل 3-6 أشهر لتقييم سيطرة سكر الدم لفترة طويلة<br />يجب على المرضى أن يحملوا معهم دائما 20 غرام غلوكوز على الأقل لأن نقص سكر الدم يمكن أن يعالج فورياً بأخذ السكر حالاً (الطعام أو الشراب الذي يحتوي على محليات صناعية مثل الطعام أوالشراب المخصص للحمية غير كافيين للسيطرة على نقص سكر الدم<br />عموماً يمكن التحويل من العوامل المخفضة لسكر الدم الفموية إلى جليمبرايد. وللتحويل إلى جليمبرايد، يجب أن يؤخذ في الاعتبار قوة والعمر النصفي للدواء المستخدم مسبقاًً. في بعض الحالات وخاصة في الأدوية المضادة للسكري التي لديها العمر النصفي طويلاً (مثل كلوربروبامايد)، ينصح بأن تكون فترة الغسول عدة أيام لتقليل خطر تفاعلات نقص سكر الدم وذلك بسبب التأثير الإضافي</p><p><strong>الاستعمال في حالة الحمل</strong><br />لم تجر دراسات على الإنسان. استناداً على نتائج الدراسات الحيوانية، لا ينصح باستعمال جليمبرايد خلال الحمل. فئة الحمل حسب منظمة الغذاء والدواء الأمريكية: فئة (ج<br /><strong>الاستعمال في حالة الارضاع</strong><br />إن توزيع جليمبرايد في حليب الأم غير معلوم. ولكن بعض السلفونيل يوريا يتوزع في حليب الام. وفي الدراسات التوالدية، لوحظ تراكيز معتبرة من جليمبرايد في حليب الفئران وفي مصل صغارهم، وبسبب قدرته في إحداث نقص سكر الدم في الأطفال الرضع، وبسبب تأثيره على الحيوانات الرضع، لا ينصح باستعمال جليمبرايد في الأمهات المرضعات</p><p dir="RTL"><strong>التداخلات الدوائية :</strong></p><p dir="RTL">-داحضات الودي، مثل عوامل حاصرات بيتا-الادريلانية: يمكن أن تضعف الداحضات الودية بعض الأعراض المطورة لنقص سكر الدم، مما يجعل كشف هذه الحالة اصعب.</p><p dir="RTL">- الكحول أو الأدوية عالية الارتباط بالبروتينات مثل الأدوية المضادة للالتهاب و الادوية اللاستيرويدية و الأدوية المضادة للتخثر و مشتق الكومارين و كلورمفينيكول و مثبطات اكسيداز أحادي الامين و بروبوبينسيد و السالسيلات و السلفومايدات: هذه الأدوية تزيد من تاثيرات نقص سكر الدم لسلفونيل يوريات عندما تتلازم معها.</p><p dir="RTL">-العوامل المسببة لفرط سكر الدم مثل: كورتيكوستيرويدات و مدرات البول و استروجينات و ايزوينازيد و نياسين و موانع الحمل الفموية و فينوثيازين و فينيتون و العوامل المحاكية الودية و هرمونات الغذة الدرقية: يمكن أن تسبب هذه الادوية فقد السيطرة على سكر الدم.</p><p dir="RTL">-ورد تقرير عن نقصان حاد في سكر الدم لوقت قصير بعد الاستعمال المترافق لبعض مشتقات السلفونيل يوريا مع مع ميكونازول</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة</strong><br /><u>الجرعة الاعتيادية للبالغين</u><br />معالجة أحادية الدواء<br />معالجة أولية: 1ملغم مرة واحدة باليوم مع الفطور أو مع أول وجبة غذائية. وإذا كان من الضروري يمكن أن تزداد الجرعة اليومية. ويجب أن تكون أي زيادة تدريجية وبناءً على مناطرة سكر الدم بحيث تكون على فترات من أسبوع إلى أسبوعين بطريقة تدريجية<br />مداومة العلاج: 1-4 ملغم مرة واحدة في اليوم. بعد الوصول إلى 2ملغم، يجب أن تتم زيادة الجرعة بزيادة تصل أقصاها إلى 2 ملغم كل أسبوع أو أسبوعين اعتماداً على استجابة غلوكوز الدم<br />يستخدم بتوليفة مع ميتفورمين: عندما لا يمكن السيطرة على مستويات سكر الدم بشكل كافٍ بالجرعة اليومية القصوى لكل من جليترا أو الأدوية المضادة للسكري المحتوية على ميتفورمين لوحدها، يمكن استخدام كلا الدوائين بشكل متلازم. في هذه الحالات، لا تتغير جرعة الدواء المستخدم أساساً وتبدأ المعالجة بالدواء المضاف بجرعة قليلة. حيث تعتمد على مستوى سكر الدم المرغوب فيه ثم يمكن أن تزداد تدريجياً حتى تصل إلى الجرعة اليومية القصوى. يجب أن تبدأ المعالجة المترافقة تحت إشراف طبي دقيق<br />يستخدم بتوليفة مع الأنسولين: عندما لا يمكن السيطرة على مستويات سكر الدم بشكل كافٍ بالجرعة اليومية القصوى لجليترا، يمكن أن يعطى بالتلازم مع الأنسولين. وفي هذه الحالة، لا تتغير الجرعة الحالية لجليترا وتبدأ المعالجة بالأنسولين بجرعة قليلة. فيما بعد يمكن أن تزداد الجرعة تدريجياً وفقاً لمستوى سكر الدم المرغوب فيه. يجب أن تبدأ المعالجة المترافقة تحت إشراف طبي دقيق<br /><strong>ملاحظات</strong><br />لم تثبت السلامة والفعالية عند الأطفال<br />يجب أن يبلع جليترا بدون مضغ ومع كمية كافية من السائل (تقريباً نصف كأس) ويؤخذ في الأوقات والجرعات الموصوفة</p><p><br /><strong>فرط الجرعة</strong><br />يمكن لفرط الجرعة بسلفونيل يوريات ويتضمن جليمبرايد ان يسبب نقص سكر الدم<br />يحتاج فرط الجرعة إلى علاج خاص<br />يجب أن يعالج أعراض نقص سكر الدم الخفيف بدون فقدان للوعي أو نتائج عصبية بتناول فوري للغلوكوز وتعديل نمط جرعات الدواء و/أو الوجبات ولكن نقص سكر الدم الحاد الذي يتضمن غيبوبة ونوبات فيتطلب مساعدة طبية طارئة فورية. ويجب أن يحقن المريض وريدياً بـ50% محلول الغلوكوز ثم يتبعه بحقن مستمر لـ 10% محلول غلوكوز للحفاظ على تركيز غلوكوز الدم 100 ملغم/ دسليتر<br />يجب أن يراقب المصابين بنقص سكر الدم الحاد لمدة 24-48 ساعة على الأقل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الاثار الجانبية<br /><u>الآثار الأقل شيوعاً: </u>نقص سكر الدم<br /><u>الآثار النادرة :</u> تفاعلات حساسية الجلد، تغيم الرؤية و/أو تغيرات في المطابقة، نقص صوديوم الدم، إسهال، دوخة، ألم معدي معوي، ألم رأس، غثيان، ضعف أو تعب غير اعتيادي، قياء، نقص الصفيحات الدموية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ حسب ظروف الحفظ المبينة على الغلاف&nbsp;<br />لا ينبغي استعمال الدواء بعد تاريخ انتهاء الصلاحية المبين على الغلاف</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>جليترا هو الاسم التجاري لجليمبرايد، وهو عامل مضاد للسكري<br />كل قرص جليترا 1 و 2 و 3 و 4 يحتوي على جليمبرايد 1 و 2 و 3 و 4 ملغم على التوالي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>علب تحتوي على 30 قرص من جليترا 1 محفوظة في أشرطة علب تحتوي على 30 قرص من جليترا 2 محفوظة في أشرطة علب تحتوي على 30 قرص من جليترا 3 محفوظة في أشرطة علب تحتوي على 30 قرص من جليترا 4 محفوظة في أشرطة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الأردنية لإنتاج الأدوية المساهمة العامة&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آذار 2005
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glitra 2 tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient:

           Glimepride 2 mg

Inactive ingredients:


Ingredient	Quantity
mg/tab.
Lactose Monohydrate	128.3
Microcrystalline Cellulose 180 m	24.45
Sodium Starch Glycolate Type A	11.9
Povidone K-25	1.7
Polysirbate 80	0.26
Red Iron Oxide 	0.2
Magnesium Stearate	1.19

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pink, shallow biconvex oblong uncoated tablets debossed with "GT 2" on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glitra is indicated for the treatment of type 2 diabetes mellitus, when diet, physical exercise and weight reduction alone are not adequate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For oral administration</p><p>The basis for successful treatment of diabetes is a good diet, regular physical activity, as well as routine checksof blood and urine. Tablets or insulin cannot compensate if the patient does not keep to the recommended diet.</p><p><strong><u>Posology</u></strong></p><p>Dose is determined by the results of blood and urinary glucose determinations.</p><p>The starting dose is 1mg glimepiride per day. If good control is achieved this dose should be used for maintenance therapy.</p><p>For the different dose regimens appropriate strengths are available.</p><p>If control is unsatisfactory the dose should be increased, based on the glycaemic control, in a stepwise manner with an interval of about 1 to 2weeks between each step, to 2, 3 or 4mg glimepiride per day.</p><p>A dose of more than 4mg glimepiride per day gives better results only in exceptional cases.</p><p>The maximum recommended dose is 6mg glimepiride per day.</p><p>In patientsnot adequately controlled with the maximum daily dose of metformin, concomitant glimepiride therapy can be initiated.</p><p>While maintaining the metformin dose, theglimepiride therapy is started with a low dose, and is then titrated up depending on the desired level of metabolic control up to the maximum daily dose. The combination therapy should be initiated under close medical supervision.</p><p>In patients not adequately controlled with the maximum daily dose of Glitra, concomitant insulin therapy can be initiated if necessary. While maintaining the glimepiride dose, insulin treatment is started at low dose and titrated up depending on the desired level of metabolic control.</p><p>The combination therapy should be initiated under close medical supervision.</p><p>Normally a single daily dose of glimepiride is sufficient. It is recommended that this dose be taken shortly before or during a substantial breakfast or -if none is taken-shortly before or during the first main meal.</p><p>If a dose is forgotten, this should not be corrected by increasing the next dose.</p><p>If a patient has a hypoglycaemic reaction on 1mg glimepiride daily, this indicates that they can be controlled by diet alone.</p><p>In the course of treatment, as an improvement in control of diabetes is associated with higher insulin sensitivity, glimepiride requirements may fall.</p><p>To avoid hypoglycaemia timely dose reduction or cessation of therapy must therefore be considered.</p><p>Change in dose may also be necessary, if there are changes in weight or life style of the patient, or other factorsthat increase the risk of hypo-or hyperglycaemia.</p><p><strong><em>Switch over from other oral hypoglycaemic agents to Glitra</em></strong></p><p>A switch over from other oral hypoglycaemic agents to Glitra can generally be done. For the switch over to Glitra the strength and the half-life of the previous medicinal product has to be taken into account. In some cases, especially inantidiabetics with a long half-life (e.g. chlorpropamide), a wash out period of a few days is advisable in order to minimise the risk of hypoglycaemic reactions due to the additive effect. The recommended starting dose is 1mg glimepiride per day.</p><p>Based on the response the glimepiride dose may be increased stepwise, as indicated earlier.</p><p><strong><em>Switch over from Insulin to Glitra</em></strong></p><p>In exceptional cases, where type2 diabetic patients are regulated on insulin, a changeover to Glitra may be indicated. The changeover should be undertaken under close medical supervision.</p><p><strong><em>Special Populations</em></strong></p><p>Patients withrenal or hepatic impairmentSee section 4.3.</p><p><strong><em>Paediatric population</em></strong></p><p>There are no data available on the use of glimepiride in patients under 8years of age.</p><p>For children aged 8 to 17years, there are limited data on glimepiride as monotherapy (see sections 5.1 and 5.2).</p><p>The available data on safety and efficacy are insufficient in the paediatric population and therefore such use is not recommended.</p><p><u>Method of administration</u></p><p>Tablets should be swallowed without chewing with some liquid&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                                    Glimepiride is contraindicated in patients with the following conditions: 

	Hypersensitivity to Glimepiride, other sulfonylureas or sulfonamides or to any of the excipients listed in section 6.1
	Diabetes mellitus type1,
	Diabetic coma, 
	Ketoacidosis,
	Severe renal or hepatic function disorders. In case of severe renal or hepatic function disorders, a change over to insulin is required.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glitra must be taken shortly before or during a meal.</p><p>When meals are taken at irregular hours or skipped altogether, treatment with Glitra may lead to hypoglycaemia.</p><p>Possible symptoms of hypoglycaemia include: headache, ravenous hunger, nausea, vomiting, lassitude, sleepiness, disordered sleep, restlessness, aggressiveness, impaired concentration, alertness and reaction time, depression, confusion, speech and visual disorders, aphasia, tremor, paresis, sensory disturbances, dizziness, helplessness, loss of self-control, delirium, cerebral convulsions, somnolence and loss of consciousness up to and including coma, shallow respiration and bradycardia.</p><p>In addition, signs of adrenergic counter-regulation may be present such as sweating, clammy skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris and cardiac arrhythmias. The clinical picture of a severe hypoglycaemic attack may resemble that of a stroke.</p><p>Symptoms can almost always be promptly controlled by immediate intake carbohydrates (sugar). Artificial sweeteners have no effect. It is known from other sulfonylureas that, despite initially successful countermeasures, hypoglycaemia may recur.</p><p>Severe hypoglycaemia or prolonged hypoglycaemia, only temporarily controlled by the usual amounts of sugar, require immediate medical treatment and occasionally hospitalisation.</p><p>Factors favouring hypoglycaemia include:</p><p>-Unwillingness or (more commonly in older patients) incapacity of the patient to cooperate,</p><p>-undernutrition, irregular mealtimes or missed meals or periods of fasting,</p><p>-alterations in diet,</p><p>-imbalance between physical exertion and carbohydrate intake,</p><p>-consumption of alcohol, especially in combination with skipped meals,</p><p>-impaired renal function,</p><p>-serious liver dysfunction,</p><p>-overdose with glitra,</p><p>-certain uncompensated disorders of the endocrine system affecting carbohydrate metabolism or counter</p><p>-regulation of hypoglycaemia (as for example in certain disorders of thyroid function and in anterior pituitary or adrenocortical insufficiency),</p><p>-concurrent administration of certain other medicinal products (see section 4.5).</p><p>Treatment with Glitra requires regular monitoring of glucose levels in blood and urine. In addition, determination of the proportion of glycosylated haemoglobin is recommended.</p><p>Regular hepatic and haematological monitoring (especially leucocytes and thrombocytes) are required during treatment with Glitra. In stress-situations (e.g. accidents, acute operations, infections with fever, etc.) a temporary switch to insulin may be indicated.</p><p>No experience has been gained concerning the use of Glitra in patients with severe impairment of liver function or dialysis patients.</p><p>In patients with severe impairment of renal or liver function change over to insulin is indicated.</p><p>Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to hemolytic anaemia. Since glimepiride belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD-deficiency and a non-sulfonylurea alternative should be considered.</p><p>Glitra contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If glimepiride is taken simultaneously with certain other medicinal products, both undesired increases and decreases in the hypoglycaemic action of glimepiride can occur. For this reason, other medicinal products should only be taken with the knowledge (or at the prescription) of the doctor.</p><p>Glimepiride is metabolized by cytochrome P450 2C9 (CYP2C9). Its metabolism is known to be influenced by concomitant administration of CYP2C9 inducers (e.g. rifampicin) or inhibitors (e.g. fluconazole).</p><p>Results from an in vivo interaction study reported in literature show that glimepiride AUC is increased approximately 2-fold by fluconazole, one of the most potent CYP2C9 inhibitors.</p><p>Based on the experience with glimepiride and with other sulfonylureas the following interactions have to be mentioned. Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur when one of the following medicinal products is taken, for example:</p><p>&sect;&nbsp; Phenylbutazone, azapropazone and oxyfenbutazone,</p><p>&sect;&nbsp; Insulin and oral antidiabetic products, such as metformin,</p><p>&sect;&nbsp; Salicylates and p-amino-salicylic acid,</p><p>&sect;&nbsp; Anabolic steroids and male sex hormones,</p><p>&sect;&nbsp; Chloramphenicol, certain long acting sulfonamides, tetracyclines, quinolone antibiotics and clarithromycin,</p><p>&sect;&nbsp; Coumarin anticoagulants,</p><p>&sect;&nbsp; Fenfluramine,</p><p>&sect;&nbsp; Disopyramide,</p><p>&sect;&nbsp; Fibrates,</p><p>&sect;&nbsp; Ace inhibitors,</p><p>&sect;&nbsp; Fluoxetine, MAO-inhibitors,</p><p>&sect;&nbsp; Allopurinol, probenecid, sulfinpyrazone,</p><p>&sect;&nbsp; Sympatholytics,</p><p>&sect;&nbsp; Cyclophosphamide, trophosphamide and iphosphamides,</p><p>&sect;&nbsp; Miconazole, fluconazole,</p><p>&sect;&nbsp; Pentoxifylline (high dose parenteral),</p><p>&sect;&nbsp; Tritoqualine.</p><p>Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of the following medicinal products is taken, for example:</p><p>&sect;&nbsp; Oestrogens and progestogens,</p><p>&sect;&nbsp; Saluretics, thiazide diuretics,</p><p>&sect;&nbsp; Thyroid stimulating agents, glucocorticoids,</p><p>&sect;&nbsp; Phenothiazine derivatives, chlorpromazine,</p><p>&sect;&nbsp; Adrenaline and sympathicomimetics,</p><p>&sect;&nbsp; Nicotinic acid (high doses) and nicotinic acid derivatives,</p><p>&sect;&nbsp; Laxatives (long term use),</p><p>&sect;&nbsp; Phenytoin, diazoxide,</p><p>&sect;&nbsp; Glucagon, barbiturates and rifampicin,</p><p>&sect;&nbsp; Acetazolamide.</p><p>H2 antagonists, beta-blockers, clonidine and reserpine may lead to either potentiation or weakening of the blood-glucose-lowering effect.</p><p>Under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine and reserpine, the signs of adrenergic counter-regulation to hypoglycaemia may be reduced or absent.</p><p>Alcohol intake may potentiate or weaken the hypoglycaemic action of glimepiride in an unpredictable fashion.</p><p>Glimepiride may either potentiate or weaken the effects of coumarin derivatives.</p><p>Colesevelam binds to glimepiride and reduces glimepiride absorption from the gastro-intestinal tract. No interaction was observed when glimepiride was taken at least for 4 hours before colesevelam. Therefore, glimepiride shouldbe administered at least 4 hours prior to colesevelam.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><em>Risk related to the diabetes</em></p><p>Abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities and perinatal mortality. So the blood glucose level must be closely monitored during pregnancy in order to avoid the teratogenic risk.</p><p>The use of insulin is required under such circumstances.</p><p>Patients who consider pregnancy should inform their physician.</p><p><em>Risk related to glimepiride</em></p><p>There are no adequate data from the use of glimepiride in pregnant women. Animal studies have shown reproductive toxicity which likely was related to the pharmacologic action (hypoglycaemia) of glimepiride (see section 5.3). Consequently, glimepiride should not be used during the whole pregnancy.</p><p>In case of treatment by glimepiride, if the patient plans to become pregnant or if a pregnancy is discovered, the treatment should be switched as soon as possible to insulin therapy.</p><p><u>Lactation</u></p><p>The excretion in human milk is unknown. Glimepiride is excreted in rat milk. As other sulfonylureas are excreted in human milk and because there is a risk of hypoglycaemia in nursing infants, breast-feeding is advised against during treatment with glimepiride.</p><p><u>Fertility</u></p><p>No data on fertilityis available</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>The patient&#39;s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p><p>Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning symptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or operate machinery in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse reactions from clinical investigations werebased on experience withGlitra and other sulfonylureas, were listed below by system organ class and inorder of decreasing incidence</p><p>(very common: &sup3;1/10; common: &sup3;1/100 to&lt;1/10; uncommon: &sup3;1/1,000 to &lt; 1/100; rare: &sup3;1/10,000 to &lt;1/1,000; very rare: &lt; 1/10,000), not known (cannot be estimated from the available data).&nbsp;</p><p><u>Blood and lymphatic system disorders</u></p><p>Rare: thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, erythropenia, haemolytic anaemia and pancytopenia, which are in general reversible upon discontinuation of medication.</p><p>Not known: severe thrombocytopenia with platelet count less than10,000/&mu;1 andthrombocytopenic purpura.</p><p><u>Immune system disorders</u></p><p>Very rare: leukocytoclastic vasculitis, mild hypersensitivity reactions that may develop into serious reactions with dyspnoea, fall in blood pressure and sometimes shock.</p><p>Not known: cross-allergenicity with sulfonylureas, sulfonamides or related substances is possible.</p><p><u>Metabolism and nutrition disorders</u></p><p>Rare: hypoglycaemia.</p><p>These hypoglycaemic reactions mostly occur immediately, may be severe and are not always easy to correct. The occurrence of such reactions depends, as with other hypoglycaemic therapies, on individual factors such as dietary habits and dose (see further under section 4.4).</p><p><u>Eye disorders</u></p><p>Not known: visual disturbances, transient, may occur especially on initiation of treatment, due to changes in blood glucose levels.</p><p><u>Gastrointestinal disorders</u></p><p>Very rare: nausea, vomiting, diarrhoea, abdominal distension, abdominal discomfort and abdominal pain, which seldom lead to discontinuation of therapy.</p><p>Rare: dysgeusia. Hepato-biliary disordersNot known: hepatic enzymes increased.</p><p>Very rare: hepatic function abnormal (e.g. with cholestasis and jaundice), hepatitis and hepatic failure.</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Not known: hypersensitivity reactions of the skin may occur as pruritus, rash, urticaria and photosensitivity.</p><p>Rare: alopecia.</p><p><u>Investigations</u></p><p>Very rare: blood sodium decrease.</p><p>Rare: weight gain.</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp; Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>After ingestion of an overdose hypoglycaemia may occur, lasting from 12 to 72hours, and may recur after an initial recovery. Symptoms may not be present for up to 24hours after ingestion. In general observation in hospital is recommended. Nausea, vomiting and epigastric pain may occur. The hypoglycaemia may in general be accompanied by neurological symptoms like restlessness, tremor, visual disturbances, co-ordination problems, sleepiness, coma and convulsions.</p><p><u>Management</u></p><p>Treatment primarily consists of preventing absorption by inducing vomiting and then drinking water or lemonade with activated charcoal (adsorbent) and sodium-sulphate (laxative). If large quantities have been ingested, gastric lavage is indicated, followed by activated charcoal and sodium-sulphate. In case of (severe) overdose hospitalisation in an intensive care department is indicated. Start the administration of glucose as soon as possible, if necessary by a bolus intravenous injection of 50ml of a 50% solution, followed by an infusion of a 10% solution with strict monitoring of blood glucose. Further treatment should be symptomatic.</p><p>In particular, when treating hypoglycaemia due to accidental intake of Glitra in infants and young children, the dose of glucose given must be carefully controlled to avoid the possibility of producing dangerous hyperglycaemia. Blood glucose should be closely monitored.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Blood glucose lowering drugs, excl. insulins: Sulfonylureas.</p><p>ATCCode: A10BB12.</p><p>Glimepiride is an orally active hypoglycaemic substance belonging to the sulfonylurea group. It may be used in non-insulin dependent diabetes mellitus.</p><p>Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells. As with other sulfonylureas this effect is based on an increase of responsiveness of the pancreatic beta cells to the physiological glucose stimulus. In addition, glimepiride seems to have pronounced extrapancreatic effects also postulated for other sulfonylureas.</p><p><u>Insulin release</u></p><p>Sulfonylureas regulate insulin secretion by closing the ATP-sensitive potassium channel in the beta cell membrane. Closing the potassium channel induces depolarisation of the beta cell and results -by opening of calcium channels-in an increased influx of calcium into the cell.</p><p>This leads to insulin release through exocytosis. Glimepiride binds with a high exchange rate to a beta cell membrane protein which is associated with the ATP-sensitive potassium channel but which is different from the usual sulfonylurea binding site.</p><p><u>Extrapancreatic activity</u></p><p>The extrapancreatic effects are for example an improvement of the sensitivity of the peripheral tissue for insulin and a decrease of the insulin uptake by the liver.</p><p>The uptake of glucose from blood into peripheral muscle and fat tissues occurs via special transport proteins, located in the cells membrane. The transport of glucose in these tissues is the rate limiting step in the use of glucose. Glimepiride increases very rapidly the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulated glucose uptake.</p><p>Glimepiride increases the activity of the glycosyl-phosphatidylinositol-specific phospholipaseC which may be correlated with the drug-induced lipogenesis and glycogenesis in isolated fat and muscle cells.</p><p>Glimepiride inhibits the glucose production in the liver by increasing the intracellular concentration of fructose-2,6-bisphosphate, which in its turn inhibits the gluconeogenesis.</p><p><u>General</u></p><p>In healthy persons, the minimum effective oral dose is approximately 0.6mg. The effect of glimepiride is dose-dependent and reproducible. The physiological response to acute physical exercise, reduction of insulin secretion, is still present under glimepiride.</p><p>There was no significant difference in effect regardless of whether the medicinal product was given 30 minutes or immediately before a meal. In diabetic patients, good metabolic control over 24 hours can be achieved with a single daily dose.</p><p>Although the hydroxy metabolite of glimepiride caused a small but significant decrease in serum glucose in healthy persons, it accounts for only a minor part of the total drug effect.</p><p><u>Combination therapy with metformin</u></p><p>Improved metabolic control for concomitant glimepiride therapy compared to metforminalone in patients not adequately controlled with the maximum dose of metformin has been shown in one study.</p><p><u>Combination therapy with insulin</u></p><p>Data for combination therapy with insulin are limited. In patients not adequately controlled with the maximum dose of glimepiride, concomitant insulin therapy can be initiated. In two studies, the combination achieved the same improvement in metabolic control as insulin alone; however, a lower average dose of insulin was required in combination therapy.</p><p><u>Special populations</u></p><p><em>Paediatric population</em></p><p>An active controlled clinical trial (glimepiride up to 8mgdaily or metformin up to 2,000mg daily) of 24 weeks&rsquo; duration was performed in 285children (8-17 years of age) with type 2 diabetes.</p><p>Both glimepiride and metformin exhibited a significant decrease from baseline in HbA1c (glimepiride-0.95 (se 0.41); metformin -1.39 (se 0.40)). However, glimepiride did not achieve the criteria ofnon-inferiority to metforminin mean change from baseline of HbA1c.The difference between treatments was 0.44% in favour of metformin. Theupper limit (1.05) of the 95% confidence interval for the differencewas not below the 0.3% non-inferiority margin.</p><p>Following glimepiride treatment, there were no new safety concerns noted in children compared to adult patients with type 2diabetes mellitus. No long-term efficacy and safety data are available in paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption: </u></p><p>The bioavailability of glimepiride after oral administration is complete. Food intake has no relevant influence on absorption, only absorption rate is slightly diminished. Maximum serum concentrations (Cmax) are reached approx. 2.5hours after oral intake (mean 0.3&mu;g/ml during multiple dosing of 4mg daily) and there is a linear relationship between dose and both Cmaxand AUC (area under the time/concentration curve).</p><p><u>Distribution</u></p><p>Glimepiride has a very low distribution volume (approx. 8.8litres) which is roughly equal to the albumin distribution space, high protein binding (&gt;99%), and a low clearance (approx. 48ml/min).</p><p>In animals, glimepiride is excreted in milk. Glimepiride is transferred to the placenta. Passage of the blood brain barrier is low.</p><p><u>Biotransformation and elimination</u></p><p>Mean dominant serum half-life, which is of relevance for the serum concentrations under multiple-dose conditions, is about 5 to 8hours. After high doses, slightly longer half-lives were noted.</p><p>After a single dose of radiolabelled glimepiride, 58% of the radioactivity was recovered in the urine, and 35% in the faeces.</p><p>No unchanged substance was detected in the urine. Two metabolites -most probably resulting from hepatic metabolism (major enzyme is CYP2C9)-were identified both in urine and faeces: the hydroxy derivative and the carboxy derivative. After oral administration of glimepiride, the terminal half-lives of these metabolites were 3 to 6 and 5 to 6hours respectively.</p><p>Comparison of single and multiple once-daily dosing revealed no significant differences in pharmacokinetics, and the intraindividual variability was very low. There was no relevant accumulation.</p><p><u>Special populations</u></p><p>Pharmacokinetics were similar in males and females, as well as in young and elderly (above 65years) patients. In patients with low creatinine clearance, there was a tendency for glimepiride clearance to increase and for average serum concentrations to decrease, most probably resulting from a more rapid elimination because of lower protein binding.</p><p>Renal elimination of the two metabolites was impaired.</p><p>Overall no additional risk of accumulation is to be assumed in such patients.</p><p>Pharmacokinetics in five non-diabetic patients after bile duct surgery were similar to those in healthy persons.</p><p><u>Paediatric population</u></p><p>A fed study investigatingthe pharmacokinetics, safety, andtolerability of a 1mg single dose of glimepiride in 30 paediatric patients (4 children aged 10-12years and 26 children aged 12-17years) with type 2 diabetes showed mean AUC (0-last), Cmax and t1/2similar to that previously observed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical effects observed occurred at exposures sufficiently in excess of the maximum human exposure as to indicate little relevance to clinical use, or were due to the pharmacodynamic action (hypoglycaemia) of the compound. This finding is based on conventional safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and reproduction toxicity studies. In the latter (covering embryotoxicity, teratogenicity and developmental toxicity), adverse effects observed were considered to be secondary to the hypoglycaemic effects induced by the compound in dams and in offspring.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Lactose Monohydrate</p><p>q&nbsp; Microcrystalline Cellulose 180 mm</p><p>q&nbsp; Sodium Starch Glycolate Type A</p><p>q&nbsp; Povidone K-25</p><p>q&nbsp; Polysorbate 80</p><p>q&nbsp; Red Iron Oxide</p><p>q&nbsp; Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at a temperature below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glitra 2 Tablets are packed in boxes of 30 Tablets blistered in PVC/ PVDC (250/40)/Aluminium Foil Blisters.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>No special requirements.</p><p>&nbsp;Any unused product or waste material should be disposed of in accordance with local requirements.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>